Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04755673 · ClinicalTrials.gov registry record · NA
Atrantil for Intestinal Bacterial Overgrowth
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT04755673 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 40 participants.
The verdict
NCT04755673, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Intestinal Bacterial Overgrowth (IBO) is a common functional condition due to excessive amounts of bacteria in the gastrointestinal tract. These bacteria ferment ingested food resulting in the production of hydrogen, methane, and carbon dioxide which subsequently can induce GI symptoms including abdominal pain, bloating, distention, diarrhea and constipation. Typically this condition is treated with antibiotics but for a portion of patients symptoms often recur. Recent work suggests that increased methane production may emanate from overgrowth of a specific type of archaebacteria, causing the aforementioned symptoms. However, no current therapies exist to treat this phenomenon. The investigators propose to trial the supplement Atrantil on patients with IMO in order to study the supplements impact on symptoms, quality of life, and methane levels.
Interventions
- OTHER Atrantil (Medical Food)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2022-09-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04755673
The ClinicalTrials.gov registry entry for NCT04755673 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atrantil (Medical Food) is the first listed.
NCT04755673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04755673 about?
NCT04755673 is a clinical study titled "Atrantil for Intestinal Bacterial Overgrowth". Intestinal Bacterial Overgrowth (IBO) is a common functional condition due to excessive amounts of bacteria in the gastrointestinal tract. These bacteria ferment ingested food resulting in the production of hydrogen, methane, and carbon dioxide which subsequently can induce GI symptoms including abd...
What is the current status of trial NCT04755673?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2020-09-18. Estimated completion is 2022-09-27.
What interventions are being tested in trial NCT04755673?
The interventions under investigation include: Atrantil (Medical Food) (OTHER).
Who is sponsoring clinical trial NCT04755673?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.